论文部分内容阅读
目的探索上皮间质化因子E-钙黏蛋白和波形蛋白表达与非小细胞肺癌铂类药物疗效相关性。方法回顾性收集2008年1月—2012年12月浙江省余姚市人民医院诊断为非小细胞肺癌、采用含铂方案治疗的患者资料及病理组织标本,以免疫组织化学染色法检测E-钙黏蛋白和波形蛋白表达,评价E-钙黏蛋白和波形蛋白表达与NSCLC临床特征的相关性,并以Kaplan-Meier生存曲线和COX回归风险比例模型评价E-钙黏蛋白和波形蛋白表达与NSCLC含铂方案治疗效果的相关性。结果共99例NSCLC患者纳入研究,肿瘤组织中E-钙黏蛋白和波形蛋白表达存显著负相关(P<0.001,r=?0.410)。中晚期、低分化、有淋巴结转移的肺癌组织E-钙黏蛋白的阳性率降低,波形蛋白阳性率增高。E-钙黏蛋白表达阳性患者OS显著高于阴性患者(中位OS 31 vs 21月,HR 0.533,95%CI:0.322~0.882,P=0.014),波形蛋白与OS无相关性。E-钙黏蛋白和波形蛋白表达与疾病进展时间无显著相关性(P>0.05)。结论 E-钙黏蛋白是一个有潜力的NSCLC铂类药物疗效的预测因子,这仍需进一步前瞻性研究验证。
Objective To explore the correlation between the expression of epithelial interstitial factor E-cadherin and vimentin and the curative effect of platinum-based non-small cell lung cancer. Methods The data and pathological specimens of patients diagnosed as non-small cell lung cancer from January 2008 to December 2012 in the People’s Hospital of Yuyao, Zhejiang Province using platinum-containing regimen were collected retrospectively. E-cadherin Protein and vimentin expression to evaluate the correlation between E-cadherin and vimentin expression and the clinical features of NSCLC. The expression of E-cadherin and Vimentin in Kaplan-Meier survival curves and the risk of COX regression model were used to evaluate the relationship between E-cadherin and vimentin expression and NSCLC Relevance of platinum regimen to treatment outcome. Results A total of 99 NSCLC patients were enrolled in the study. There was a significant negative correlation between E-cadherin and vimentin expression in tumor tissues (P <0.001, r = -0.410). In the advanced stage, the positive rate of E-cadherin in lung cancer tissues with poorly differentiated and lymph node metastasis decreased, and the positive rate of vimentin increased. The OS of patients with positive E-cadherin expression was significantly higher than that of negative patients (median OS 31 vs 21 months, HR 0.533, 95% CI: 0.322-0.882, P = 0.014). There was no correlation between vimentin and OS. E-cadherin and vimentin expression and disease progression time was not significantly correlated (P> 0.05). Conclusions E-cadherin is a potential predictor of the efficacy of platinum-based NSCLC drugs, which remains to be further prospectively validated.